The Cardiovascular Drugs market size was estimated at USD 168.36 billion in 2023 and is projected to reach USD 221.85 billion in 2030 at a CAGR of 4.02% during the forecast period 2023-2030.
Cardiovascular drugs are medications that are used to treat various conditions related to the heart and blood vessels. They are prescribed to manage heart diseases and other cardiovascular disorders. Cardiovascular medicines are often used in combination to treat different aspects of a cardiovascular disease. There are various types of cardiovascular drugs such as antihypertensives that are used to lower blood pressure, anticoagulants that are used to prevent blood clots, antihyperlipidemic that are used to lower cholesterol and triglyceride levels, antiarrhythmics that are used to regulate abnormal heart rhythms. Most cardiovascular drugs are prescribed to treat hypertension and dyslipidaemia which are majorly responsible for the formation of atherosclerotic plaque within blood vessels restricting blood flow to the body parts resulting in multiple cardiac indications such as stroke, heart failure, cardiomyopathy, peripheral artery disease, and venous thrombosis.
The cardiovascular drugs market can be segmented based on drug class into anti-hyperlipidaemic, anti-hypertensives, anti-coagulants, anti-arrhythmic and others. Based on indication the market can be bifurcated into hypertension, hyperlipidaemia, coronary artery disease, arrhythmia and others. Based on distribution channel, the market can be segmented into hospital, pharmacies and others. Lastly, based on region the market is bifurcated into North America, Europe, Asia-Pacific, Middle East and Africa and South America. Rising prevalence of cardiovascular diseases (CVDs) globally, growing research and development and investment in efficient drug development and increasing availability of reimbursement policies are the factors that are contributing to the growth of the market during the forecast period. Moreover, the increasing number of admissions in hospitals, as well as critical care units owing to cardiovascular diseases (CVDs) has created demand for the development of cardiovascular drugs for treatment.
The COVID-19 pandemic affected healthcare systems globally and resulted in the interruption of usual care in many healthcare facilities, exposing vulnerable patients with cardiovascular diseases to significant risks. However, the demand for cardiovascular drugs increased during the pandemic owing to the increased risk of infection among patients with cardiovascular diseases (CVDs).
During the pandemic, increased risk of infection among patients with CVDs led to an increase in the demand for cardiovascular drugs which drove the market during the pandemic. The cardiovascular drugs market is further expected to grow during the forecast period. This growth can be attributed to factors such as growing research and development, increased investment in efficient drug development and increasing availability of reimbursement policies. In addition to that, increasing prevalence of cardiovascular diseases among the population leading to increase in number of admissions in hospitals as well as critical care units has led to increased demand for cardiovascular drugs for treatment.
North America to Dominate the Market
